WO2004058970A1 - アディポネクチンプロモーターおよびその用途 - Google Patents
アディポネクチンプロモーターおよびその用途 Download PDFInfo
- Publication number
- WO2004058970A1 WO2004058970A1 PCT/JP2003/016772 JP0316772W WO2004058970A1 WO 2004058970 A1 WO2004058970 A1 WO 2004058970A1 JP 0316772 W JP0316772 W JP 0316772W WO 2004058970 A1 WO2004058970 A1 WO 2004058970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syndrome
- sequence
- regulator
- dna
- screening
- Prior art date
Links
- 108010076365 Adiponectin Proteins 0.000 title description 30
- 102000011690 Adiponectin Human genes 0.000 title description 25
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 claims abstract description 80
- 102000057799 human ADIPOQ Human genes 0.000 claims abstract description 69
- 230000000694 effects Effects 0.000 claims abstract description 57
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 51
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 238000012216 screening Methods 0.000 claims abstract description 39
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims abstract description 14
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 9
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 230000003449 preventive effect Effects 0.000 claims abstract description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 5
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims abstract description 5
- 235000020824 obesity Nutrition 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 78
- 239000013612 plasmid Substances 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 15
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 229940126585 therapeutic drug Drugs 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 230000002498 deadly effect Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 239000002585 base Substances 0.000 description 25
- -1 inorganic acid salts Chemical class 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 239000005089 Luciferase Substances 0.000 description 18
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 18
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 102000006255 nuclear receptors Human genes 0.000 description 16
- 108020004017 nuclear receptors Proteins 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 108010038912 Retinoid X Receptors Proteins 0.000 description 13
- 102000034527 Retinoid X Receptors Human genes 0.000 description 13
- 239000000539 dimer Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000013613 expression plasmid Substances 0.000 description 9
- 229960005095 pioglitazone Drugs 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003889 eye drop Substances 0.000 description 8
- 229940012356 eye drops Drugs 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 6
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 6
- 101150050070 RXRA gene Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000012865 aseptic processing Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000055401 human NR5A2 Human genes 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 101100440911 Homo sapiens CYP7A1 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100440915 Rattus norvegicus Cyp7a1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GKEMUBZAKCZMKO-UHFFFAOYSA-N ethane-1,2-diol;ethene Chemical group C=C.OCCO GKEMUBZAKCZMKO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000006451 grace's insect medium Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 102000046668 human RXRA Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- the present invention relates to a promoter containing a single nucleotide sequence of a novel regulator for gene expression and its use. Specifically, a DNA containing a promoter region containing a human adiponectin gene regulator sequence, a transformant transformed with the DNA, a compound that promotes adiponectin promoter activity through the regiulator sequence, or It relates to methods for screening the salts.
- Conventional technology a DNA containing a promoter region containing a human adiponectin gene regulator sequence, a transformant transformed with the DNA, a compound that promotes adiponectin promoter activity through the regiulator sequence, or It relates to methods for screening the salts.
- Conventional technology Conventional technology
- Adipose tissue has traditionally been considered to be a passive tissue that stores fat, but has recently been regarded as an endocrine tissue that actively produces and secretes various bioactive factors.
- Adipocytes that form adipose tissue secrete various bioactive factors called adipocytokines and have recently been shown to play a crucial role in the regulation of systemic glucose and lipid metabolism (Nature, vol. 414, 2001). Year, see pages 799-806).
- Adiponectin was identified as the most abundantly expressed gene in human adipocytes and as honolemon (see Biochemical and Biophysical Research Communication, Vol. 221, 1996, pp. 286-289). Adiponectin is produced and secreted specifically in fat cells, and is abundant in the blood.
- adiponectin is a hormone that has anti-diabetic, anti-atherosclerotic, and anti-obesity effects, and is deeply involved in the development and progression of metabolic diseases.
- plasma adiponectin levels are reduced in patients with ischemic heart disease and insulin-resistant diabetes (Circulation, 100, 1999, 2473-2476).
- P. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2000, pp. 1595-1599).
- a decrease in plasma adiponectin concentration was correlated with the onset of insulin-resistant diabetes and arteriosclerosis (see Diabetes, Vol.
- mice deficient in the adiponectin gene high sucrose and high-fat diets induced diabetes, and arterial thickening was markedly increased when the arteries were damaged.
- the lesions were markedly improved (Nature Medicine, Vol. 8, 2002, pp. 731-737, Journal of Biological Chemistry, 277, 2002). Year, pp. 37487-37491).
- mice deficient in apolipoprotein E administration of the adiponectin gene using adenovirus suppressed the progression of arteriosclerosis (see Circulation, Volume 106, 2002, 2767-2770).
- Administration of recombinant adiponectin protein to mice with metabolic abnormalities showed an improvement in insulin resistance and a hypoglycemic effect (Nature Medicine, Vol. 7, 2001, pages 941-946, Nature Medicine, Vol. 7, 2001). , Pp. 947-953).
- treatments that increase plasma adiponectin levels in patients with metabolic syndrome associated with hypoadiponectinemia may be effective in improving the condition.
- the plasma concentration of adiponectin in humans is 5-20 ⁇ g / m1 (see Biochemical and Biophysical Research Communication, 257, 1999, pp. 79-83), which is absolutely lower than that of other blood hormones.
- the quantity is extremely high.
- supplementation therapy with recombinant adiponectin protein aimed at normalization of plasma concentration requires continuous high-dose administration of the protein and in vivo enzymes of the protein. It is thought that various major difficulties are involved, including prevention of decomposition. Disclosure of the invention
- protein production can be regulated at various stages, the most fundamental of which is transcription from genes to messenger RNA.
- One of the most effective means is to modify the amount of protein produced by regulating the expression of disease-related genes to improve the condition of the disease. Transcription is controlled by a promoter region located near the base sequence to be transcribed into messenger RNA.
- a base sequence called a regulator sequence existing in the promoter region is used to regulate a specific protein as a transcription control factor. It is important that the quality binds.
- transcription factors are a group of proteins called nuclear receptors that exert their actions by binding to low molecular weight molecules (ligands).
- PPAR Peroxisome Proliferator-Activated Receptor 7
- RXR Retinoid X Receptor
- PPARY is activated by an unspecified endogenous ligand or an exogenous ligand such as a thiazolidinedione derivative (Annu. Rev. Biochem., 70, 341-367 (2001)).
- the regulator sequence PPRE is composed of a characteristic nucleotide sequence represented by 5, -AGGTCA n AGGTCA-3, but the nucleotide sequence is slightly different depending on the type of gene having PRE.
- a drug that modulates the expression of a gene to improve its disease state by changing its protein production its activity is regulated by a small molecule ligand present in the promoter region of the gene.
- Identification of nuclear receptor regulator sequences is an efficient and And it is useful for constructing the best screening system to find drug candidate compounds. Therefore, a transformant produced by identifying a regulator sequence present in the human adiponectin gene promoter region that regulates its transcriptional activity and linking the DNA containing the regulatory sequence to an appropriate reporter gene is produced.
- adiponectin gene expression such as diabetes, obesity, hypercholesterolemia, hyperlipoproteinemia, and other metabolic disorders, hyperlipidemia, arteriosclerosis, hypertension, cardiovascular disease, bulimia, etc.
- the transformant further prevents various syndromes caused by the above diseases (syndrome X, metabolic syndrome, multiple risk factor syndrome, insulin resistance syndrome, quartet of death, visceral fat syndrome, etc.). Or as a useful screening system for therapeutic agents.
- the regulator sequence involved in the regulation of expression of the human adiponectin gene has not been identified, and there has been no method capable of effectively screening for an expression promoting substance.
- the present inventors have conducted intensive studies with the aim of establishing a screening method for searching for an adiponectin gene expression promoting substance.
- the human adiponectin gene 5 a regulator sequence specific to the adiponectin gene, PPRE, was located in the upstream promoter region.
- LRH—RE liver receptor homologue-1 responsive element
- a DNA comprising a promoter region having the nucleotide sequence represented by SEQ ID NO: 1, wherein the DNA comprises a human adiponectin regulator sequence; 2.
- regulator sequence is a nucleotide sequence having both the nucleotide sequence represented by SEQ ID NO: 2 and the nucleotide sequence represented by SEQ ID NO: 3.
- Syndrome X metabolic syndrome, multiple risk factor syndrome, insulin, wherein the transformant according to 11 is used.
- a method for screening for a prophylactic and / or therapeutic agent for a syndrome selected from the group consisting of:
- the disease that causes the syndrome is diabetes, obesity, hypercholesterolemia, hyperlipoproteinemia and other metabolic disorders, hyperlipidemia, arteriosclerosis, high blood pressure, cardiovascular disease, or bulimia
- a screening kit for a compound or a salt thereof which promotes human adiponectin promoter activity characterized by using the transformant according to the above-mentioned 11;
- a compound or a salt thereof that promotes human adiponectin promoter one activity obtained by using the screening kit according to 15 above,
- a symptom group selected from Syndrome X, Metapolic Syndrome, Multiple Risk Factor 1 Syndrome, Insulin Resistance Syndrome, Insulin Resistance Syndrome, quartet of Death, and Visceral Fat Syndrome obtained by using the screening kit according to 16 above.
- Prophylactic and / or therapeutic drugs are included in the screening kit according to 16 above.
- a pharmaceutical composition comprising the compound or a salt thereof which promotes human adiponectin promoter activity according to the above item 17 or 19, and 22.
- a medicament comprising a preventive and / or therapeutic drug for a syndrome selected from the syndrome X, metapolic syndrome, multiple risk factor syndrome, insulin resistance syndrome, death quartet, and visceral fat syndrome according to the above 18 or 20, Composition.
- the DNA of the present invention comprising a regulator A sequence in the human adiponectin gene promoter region P PRE or LRH-RE, or a DNA containing both P PRE and LRH-RE contains the regulator sequence and has adiponectin promoter activity. Anything can be used. Specifically, any nucleotide may be used as long as it contains the nucleotide sequence represented by SEQ ID NO: 1, its complementary sequence, or a part thereof. Further, any of genomic DNA, cDNA and synthetic DNA derived from humans may be used.
- the recombinant DNA containing the promoter region containing either the regulator sequence P PRE or LRH-RE of the human adiponectin promoter region or both in the present invention can be specifically obtained as follows.
- a primer corresponding to the previously reported nucleotide sequence of the human adiponectin promoter region (Int. J. Obes. Relat. Metab. Disord., 24, 861-868 (2000)) was designed, and a human tissue-derived genome was designed.
- the target DNA fragment is amplified by a PCR method using DNA (eg, Clontech) as a type I PCR.
- the obtained DNA is cloned into a plasmid for E. coli or the like, and the nucleotide sequence is determined.
- the obtained DNA can be used as it is or by digesting with a restriction enzyme or adding a linker depending on the purpose.
- reporter gene whose transcript amount can be detected is ligated downstream of the obtained DNA
- reporter genes luciferase gene, chloramphenicol acetyltransferase gene, alkaline phosphatase gene, ⁇ -galactosidase gene and the like are widely used. ⁇ ⁇ ⁇ ⁇ Any other structural gene can be used if its gene product is detectable.
- yeast As a host to be transformed with the recombinant plasmid DNA, yeast, insect cells, animal cells and the like are used.
- yeast include Saccharomyces cerevisiae AH22R-, NA87-11A, DKD-5D and the like.
- insect cells for example, night rob moth Sf9 cells, silkworm BmN cells, and the like are used.
- animal cells include sal COS-1 cells, COS-7 cells, Chinese hamster CHO cells, mouse L cells, 293T cells, 3T3-L1 cells, human HEK293 cells, HepG2 cells, and white fat cells. Cells that are induced to differentiate under appropriate differentiation conditions are used.
- Transformation of insect cells can be carried out, for example, by appropriately modifying the method described in Bio / Technology, vol. 6, 47, (1988).
- a method described in Cell Engineering Annex 8 New Cell Engineering Experimental Protocol, 263 (published by Shujunsha in 1995) or Virology, vol. 52, 456 (1973) is used. It can be carried out with appropriate modification.
- the transformant is cultured in the presence of a specific compound, and the ability of the compound to promote promoter activity can be known by measuring and comparing the amount of the gene product in the culture.
- the culture medium may be, for example, Burkholder minimal medium (Proc. Natl. Acad. Sci. USA , vol.77, 4505 (1980)).
- the pH of the medium is adjusted to about 5-8. Cultivation is usually carried out at about 20 ° C to 30 ° C for about 24 to 72 hours, and if necessary aeration and agitation. Add stirring.
- a medium for example, Dulbecco's modified Idal medium (Nakarai) containing about 5 to 20% fetal bovine serum is used.
- the pH of the medium is adjusted to about 6-8. Cultivation is usually performed at about 30 ° C to 40 ° C for about 15 to 60 hours, and if necessary, aeration and stirring are added.
- the DNA of the present invention is a DNA containing a promoter region containing one or both of the human adiponectin promoter region and the regulatory sequence P PRE or LRH-RE, by using a transformant thereof, Compounds or salts thereof that promote the activity of the human adiponectin promoter can be screened.
- the screening method, the screening kit, the screening method, and the compound or salt thereof that promotes the human adiponectin promoter activity obtained by using the screening kit will be specifically described.
- the human adiponectin promoter region regulator sequence P PRE or LRH-RE of the present invention, or a DNA containing a promoter region containing either or both, and a transformant transformed with the DNA are human adiponectin It is useful for screening a compound or a salt thereof that promotes the activity of a promoter.
- the method for determining a compound or a salt thereof which promotes the activity of the human adiponectin promoter of the present invention comprising contacting the transformant of the present invention with a test compound and the method comprising not including a sequence of the regulator of the present invention, It is characterized by measuring and comparing the expression level of polypeptide when the transformant is brought into contact with the test compound.
- Test compounds include peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, and the like. These compounds may be novel compounds or known compounds.
- a polypeptide encoded by the above structural gene preferably a reporter gene or the like is used.
- a method for measuring the expression level of a polypeptide for example, a method similar to the method of Brasier, AR et al. (Biotechniques vol. 7, 1116-1122 (1989)) may be used to measure ⁇ "luciferase activity. Can be
- the screening kit for a compound or a salt thereof that promotes the activity of the human adiponectin promoter of the present invention is characterized by using the above-mentioned transformant, and examples thereof include the following.
- Cell culture medium Dulbecco's modified Eagle's medium (Nakarai) supplemented with 5% inactivated fetal serum (JRH Biosciences).
- Plasmid for measuring human adiponectin promoter activity The DNA of the present invention, which contains both the regulator sequence of the human adiponectin promoter region PRE and LRH-RE, is inserted into the multicloning site of the luciferase gene-containing pGL3-basic vector (Promega). What was inserted. Plasmids for nuclear receptor expression: full length of human PPARy, human RXR, and human LRH-1. 08 are obtained by the PCR method using a human cDNA library (Clontech) as a template. Acquired cDNA and expression for mammalian cells Use a plasmid that has been treated with the same restriction enzyme and ligated.
- Host cell line HEK293 cells (human embryonic kidney-derived cell line, obtained from ATCC)
- Test compound Store in aqueous solution at 4 ° C or 120 ° C, and use in cell culture medium before use Dilute to 50. Test compounds that are poorly soluble in water should be dissolved in dimethyl sulfoxide, ethanol, etc.
- HEK 293 cells were seeded into 96-well multiplate (Nunc), cultured overnight at 37 ° C, 5% C0 2 conditions.
- the method for gene transfer is based on the method described in Lu et al.'S report (Mol. Cell, 6, 507-515 (2000)).
- the plasmid for measuring the activity of the human adiponectin promoter of the present invention is transiently introduced into cells using a 50 ng / well hole and a plasmid for expressing a nuclear receptor at 15 ng / well, respectively, using the calcium phosphate method. Eight hours after gene transfer, add 1/5 of the test compound dilution to the culture supernatant.
- a compound that promotes human adiponectin promoter activity is found using the above-described screening method or screening kit, the compound will increase adiponectin production and secretion in adipose tissue, and as a result, increase plasma adiponectin concentration
- the compound is further used as a prophylactic / therapeutic agent for various syndromes caused by the above diseases (Syndrome X, metabolic syndrome, multiple risk factor syndrome, insulin resistance syndrome, quartet of death, visceral fat syndrome, etc.). Can be used.
- non-toxic salt of the compound obtained by using the above-described screening method or screening kit examples include salts of alkali metals (such as potassium, sodium, and lithium) and salts of alkaline earth metals (such as calcium and magnesium). Salts, ammonium salts (tetramethylammonium salts, tetrabutylammonium salts, etc.), organic amines (triethylamine, methylamine, dimethylamine, cyclopentinoleamine, penzinoleamine, phenethylenamine, piperidin, monoethanolamine) Min, diethanolamine, tris (hydroxymethyl) methylamine, lysine, arginine, N-methyl-D-dalcamine, etc.
- alkali metals such as potassium, sodium, and lithium
- alkaline earth metals such as calcium and magnesium.
- salts acid adduct salts (inorganic acid salts (hydrochloride, hydrobromide, borohydride) Hydrochloride, sulfate, phosphate, nitric acid Etc.), organic acid salts (acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate, ethanesulfonate, Benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate, etc.).
- organic acid salts acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate, ethanesulfonate, Benzenesulfonate, toluenesulfonate, isethionate, glucuronate, glu
- the non-toxic salt of the compound of the present invention also includes a solvate or a solvate of the above-mentioned alkali (earth) metal salt, ammonium salt, organic amine salt or acid adduct salt of the compound of the present invention.
- the solvate is non-toxic and water-soluble.
- Suitable solvates include, for example, solvates such as water and alcohol solvents (such as ethanol).
- a solid preparation for oral administration a liquid preparation for internal use, an injection for parenteral administration, an external preparation, and a suppository It is used as an agent.
- Solid preparations for oral administration include tablets, pills, capsules, powders, granules and the like. Capsules include hard capsules and soft capsules.
- the active substance is used as is, or excipients (ratatose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (hydroxypropylcellulose, polybutylpyrrolidone, Mixed with magnesium aluminate metasilicate, disintegrant (calcium cellulose glycolate, etc.), lubricant (magnesium stearate, etc.), stabilizer, dissolution aid (glutamic acid, aspartic acid, etc.) It is formulated and used according to the usual method.
- a coating agent sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- capsules of absorbable materials such as gelatin.
- Liquid preparations for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like.
- the active substance is dissolved, suspended or emulsified in a commonly used diluent (eg, purified water, ethanol or a mixture thereof).
- the liquid preparation may contain a wetting agent, a suspending agent, an emulsifying agent, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- Injections for parenteral administration include solutions, suspensions, emulsions, and solid injections that are used by dissolving or suspending in a solvent for use.
- Injectables are used by dissolving, suspending or emulsifying the active substance in a solvent.
- a solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, or a combination thereof are used.
- this injection contains a stabilizer, a solubilizer (glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, and the like. Is also good. These are manufactured by sterilization or aseptic processing in the final step.
- a sterile solid preparation for example, a freeze-dried product
- Topical dosage forms for parenteral administration include, for example, ointments, gels, tablets, poultices, patches, liniments, sprays, inhalants, sprays, aerosols, eye drops And nasal drops. They contain the active substance and are prepared by known methods or commonly used formulations.
- the ointment is manufactured by a known or commonly used formulation. For example, it is prepared by mixing or melting the active substance with a base.
- the ointment base is selected from known or commonly used ones. For example, higher fatty acids or higher fatty acid esters (adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid esterol, panolemitic acid ester, stearic acid ester, oleic acid ester, etc.), waxes ( Millo®, spermaceti, ceresin, etc.), surfactants (polyoxyethylene alkyl ether phosphate ester, etc.), higher alcohols (cetanol, stearyl alcohol, setosteryl alcohol, etc.), silicone oil (dimethyl polysiloxane, etc.) ), Hydrocarbons (hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin, etc.), glyco
- the gel is produced by a known or commonly used formulation. For example, it is produced by melting an active substance in a base.
- the gel base is selected from known or commonly used ones.
- lower alcohols ethanol, isopropyl alcohol, etc.
- gelling agents carboxymethylcellulose, hydroxyxetinoresenorelose, hydroxypropinoresenorelose, ethylsenorelose, etc.
- neutralizing agents triethanol, etc.
- Surfactants eg, polyethylene glycol monostearate
- gums water, absorption enhancers, and rash preventives can be used alone or as a mixture of two or more. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- the cream is produced by a known or commonly used formulation. For example, it is prepared by melting or emulsifying the active substance in a base.
- the cream base is selected from those known or commonly used. For example, higher fatty acid esters, lower alcohols, hydrocarbons, polyhydric alcohols (propylene glycol, 1,3-butylene glycol, etc.), higher alcohols (2-hexyldecanol, cetanol, etc.), emulsifiers (polyoxyethylene alkyl) Ethers, fatty acid esters, etc.), water, absorption enhancers, and rash preventives, singly or in combination of two or more. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- the poultice is produced by a known or commonly used formulation. For example, it is produced by melting an active substance in a base material, forming a kneaded product, and spreading and applying the mixture on a support.
- the compress base is selected from known or commonly used ones. For example, thickeners (polyacrylic acid, polybutylpyrrolidone, gum arabic, starch, gelatin, methyl cellulose, etc.), wetting agents (urea, glycerin, propylene glycol, etc.), fillers (kaolin, zinc oxide, talc, calcium, Magnesium, etc.), water, dissolution aids, tackifiers, and anti-rash agents are used alone or in combination of two or more. Further, they may contain preservatives, antioxidants, flavoring agents and the like.
- the patch is produced by a known or commonly used formulation. For example, it is manufactured by melting an active substance in a base material and spreading and applying the composition on a support.
- the base for the patch is selected from known or commonly used ones. For example, one selected from a polymer base, oils and fats, higher fatty acids, tackifiers and anti-rash agents may be used alone or in combination of two or more. In addition, preservatives, antioxidants, flavors Etc. may be included.
- the liniment is manufactured by a known or commonly used formulation.
- the active substance is dissolved, suspended or emulsified in one or more selected from water, alcohol (ethanol, polyethylene glycol, etc.), higher fatty acids, glycerin, soap, emulsifier, suspending agent, etc. Be prepared.
- preservatives, antioxidants, flavoring agents and the like may be included.
- Sprays, inhalants, sprays and nasal drops may be used in addition to commonly used diluents, buffers to give isotonicity with stabilizers such as sodium bisulfite, for example sodium chloride, sodium taenate or It may contain isotonic agents such as citric acid.
- stabilizers such as sodium bisulfite, for example sodium chloride, sodium taenate or It may contain isotonic agents such as citric acid.
- a nasal drop When a nasal drop is administered, it is usually sprayed quantitatively into the nasal cavity with a solution or powder containing the drug and using a special nasal dropper or nebulizer.
- Ophthalmic solutions for parenteral administration include eye drops, suspension-type eye drops, emulsion-type eye drops, B-jira-dissolved-type eye drops, and ointments.
- the active substance is used by dissolving, suspending or emulsifying in a solvent.
- a solvent for the eye drops for example, sterilized purified water, physiological saline, other aqueous solvents or non-aqueous preparations for injection (eg, vegetable oil) and the like, and combinations thereof are used.
- Eye drops include isotonic agents (sodium chloride, concentrated glycerin, etc.), buffering agents (sodium phosphate, sodium acetate, etc.), surfactants (polysorbate 80 (trade name), polyoxyl stearate 40, Polyoxyethylene hydrogenated castor oil, etc.), stabilizing agents (sodium citrate, sodium edetate, etc.), preservatives (benzalkonium chloride, paraben, etc.) and the like may be appropriately selected and included as necessary. . These are manufactured by sterilizing power and aseptic processing in the final process. It is.
- a sterile solid preparation for example, a lyophilized product
- a sterile solid preparation for example, a lyophilized product
- inhalants for parenteral administration include aerosols, powders for inhalation, and solutions for inhalation.
- the inhalation solution is used by dissolving or suspending in water or other appropriate medium at the time of use. It may be in a form. These inhalants are manufactured according to a known method.
- preservatives benzalkonium chloride, paraben, etc.
- coloring agents for example, coloring agents, buffering agents (sodium phosphate, sodium acetate, etc.), tonicity agents (sodium chloride, concentrated glycerin, etc.)
- buffering agents sodium phosphate, sodium acetate, etc.
- tonicity agents sodium chloride, concentrated glycerin, etc.
- a thickener such as a riboxyvinyl polymer
- an absorption enhancer as needed.
- lubricants stearic acid and its salts, etc.
- binders starch, dextrin, etc.
- excipients lactose, cellulose, etc.
- coloring agents preservatives (salts, etc.) It is prepared by appropriately selecting, as necessary, luconium, paraben, etc.) and an absorption enhancer.
- a nebulizer (atomizer, nebulizer) is usually used to administer inhaled liquids, and a powdered inhaler is usually used to administer inhaled powders.
- compositions for parenteral administration include suppositories for rectal administration and pessaries for vaginal administration, which contain the active substance and are formulated in a conventional manner.
- the preparation thus obtained is safe and has low toxicity, it can be administered to, for example, human mammals (for example, rats, mice, rabbits, cats, dogs, monkeys, etc.).
- the dosage of the compound or a salt thereof varies depending on the age, body weight, symptom, therapeutic effect, administration method, treatment time, and the like, but is generally within a range of 1 ng to 100 mg per adult per dose.
- FIG. 1 shows the nucleotide sequence of DNA containing the promoter region of human adiponectin.
- FIG. 2 shows the structures of the human adiponectin promoter / reporter plasmid DNA and various promoter-deleted DNAs.
- FIG. 3 shows the transcription promoting activity of the human adiponectin promoter reporter plasmid DNA by constitutively activated PPART / and RXRa.
- FIG. 4 shows the transcription promoting activity of human adiponectin promoter Z reporter plasmid DNA and various promoter-deleted DNAs.
- FIG. 5 shows a comparison of the nucleotide sequence of PPRE having a group of genes transcriptionally regulated by the PPAR dimer.
- FIG. 6 shows the structures of the PRE sequence on the human adiponectin gene and the reporter plasmid DNA of the human adiponectin promoter with a mutation introduced into the PPRE sequence.
- FIG. 7 shows the transcription-promoting activity of the mutant promoter Noreporter Plasmid DNA by the constitutively active DNAPPARy and RXR.
- FIG. 8 shows the direct binding of the PPARyZRXR dimer to the regulator sequence P PRE of the human adiponectin promoter (gel shift assay).
- FIG. 9 shows a comparison of the base sequences of LRH-REs of genes that are transcriptionally regulated by LRH-1.
- FIG. 10 shows the structures of the LRH-RE sequence on the human adiponectin gene and the DNA of the human adiponectin promoter Z repo-plasmid plasmid having a mutation introduced into the LRH-RE sequence.
- FIG. 11 shows the transcription promoting activity of human adiponectin promoter Z reporter plasmid DNA by pioglitazone when PPARyZRXR dimer and LRH-1 were expressed.
- FIG. 12 shows the direct binding of the human adiponectin promoter of LRH-1 to the regulatory regulator sequence LRH-RE (gel shift assay).
- FIG. 13 shows the transcription promoting activity of human adiponectin promoter Z reporter plasmid DNA in differentiated adipocytes by pioglitazone.
- Example 1 Construction of human adiponectin promoter Z reporter plasmid DNA
- DNA containing the promoter region of human adiponectin was obtained by PCR using the DNA fragment (Int. J. Obes. Relat. Metab. Disord, 24, 861-868 (2000)) obtained by the method of Takahashi et al. Amplified.
- a clone containing a human adiponectin gene was obtained from human Pl-derived artificial chromosome (PAC) DNA pools (Genome Systems) and digested with restriction enzymes BamHI and XbaI.
- PAC Pl-derived artificial chromosome
- the DNA fragment was designated as type I, and the transcription start site of the human adiponectin gene was designated as base number 1 from 5 'upstream 908th to 3' downstream 1 Primers designed to amplify up to the fourth nucleotide sequence (5, -TTT CGG GGT ACC GCT TCT AGG CCA GAG CTG GG TTC-3 '(SEQ ID NO: 5) and 5, -TTT CGG GAG CTC CTG CAG TCA
- the DNA fragment containing the human adiponectin promoter region was amplified by PCR using GAA TGG AAG TGA GAA-3 ′ (SEQ ID NO: 6)), and the nucleotide sequence was determined.
- Figure 1 shows the determined nucleotide sequence.
- the amplified DNA fragment and the pGL3 basic plasmid (Promega) having the firefly luciferase gene were digested with restriction enzymes KpnI and SacI, respectively, and both were ligated.
- Figure 2 shows the outline of the structure.
- this human adiponectin promoter / reporter plasmid is referred to as p (-908) ZLUC.
- Example 2 Assay for transcription promoting activity of human adiponectin promoter reporter plasmid DNA
- Example 2 The activation of the p (-908) ZLUC constructed in Example 1 by a dimer of the nuclear receptor PPAR / RXR was assayed by luciferase assay.
- Example 2 the chimeric proteins (VP16-PPAR7, and VP16-RXR ⁇ ) in which the transcription activation region of the herpesvirus protein VP16 and the nuclear receptor PPARy and RXRo; The activity was assayed by introducing a gene into an expression plasmid DNA that expresses in a cell. These chimeric nuclear receptors have the ability to activate the transcription of response genes without depending on the respective activation ligands (Mol. Endocrinol. 16, 1040-1048 (2002)).
- p (-908) ZLUC constructed in Example 1 was transfected simultaneously with the nuclear receptor expression plasmid.
- HEK293 cells derived from human fetal kidney were used as host cells. Cells are seeded on a 96-well multiplate (Nunc) and immobilized 5% Using Dulbecco's modified Eagle's medium containing fetal serum (Nacalai Inc.) were cultured overnight at 37 ° C, 5% C0 2 under the conditions, were transformed. The method of gene transfer followed the method described in Lu et al.'S report (Mol. Cell 6, 507-515 (2000)).
- a human adiponectin promoter-deleted mutant having the structure shown in the lower part of FIG. 2 was prepared for the purpose of specifying which region on the human adiponectin motor increases the transcriptional activity observed in Example 2. . 5.
- a primer having a restriction enzyme cleavage site at the end was designed so as to obtain a promoter DNA of a desired length, and was amplified by PCR using the p (-908) ZLUC described above as a type III. Amplified DNA fragment and pGL3 Basic Plus The mid (pGL3 basic plasmid) was digested with a restriction enzyme and ligated to construct a deletion mutant.
- each of these deletions was used as a reporter to transiently express both VP16-PPARy and VP16-RXR ⁇ expression plasmids, and luciferase was treated in the same manner as in Example 2. Activity was measured.
- Fig. 4 shows the results. Deletion of the sequence from 286 bp to 267 bp in the human adiponectin promoter region eliminated the increase in luciferase activity due to the expression of both VP16-PPAR ⁇ and VP16-RXRa. From these results, it was presumed that there was a regulatory sequence P PRE on which the PPAR ⁇ / RXR dimer acts, between 1 286 bp and 1 267 bp of the human adiponectin promoter region.
- Figure 5 shows the nucleotide sequence of PPRE present in the promoter region of a gene reported to be transcriptionally regulated by PPARoz / RXR dimer (Genes Dev., 8, 1224-1234 (1994) Chem., 275, 9131-9135 (2000), Mol. Cell, 7, 161-171 (2001), J. Biol. Chem., 276, 48572-48579 (2001)). Each has a similar structure consisting of 13 bases called direct repeat 1 (DR1).
- DR1 direct repeat 1
- a reporter plasmid was prepared in which a two-base mutation was introduced into the deduced sequence, as shown in FIG. Mutations were introduced using the QuikChange Site-Directed Mutagenesis kit (Stratagene) according to the attached protocol.
- VP was transferred to HEK293 cells. 16—? ? 1 7 and ⁇ ?
- a gel shift assay was performed to confirm that the PPAR YZRXR dimer directly binds to the regulator sequence P PRE identified from 1 285 bp to 1 273 bp of the human adiponectin promoter region.
- P PAR gamma RXRA protein is human PPARy, an expression plasmid expressing human RXRA and ⁇ , using T N T T7 Quick Coupled Transcription / Translation Systems ( Promega) attached protocol was synthesized in an in vitro system.
- Oligo DNA (5, -TGG TTT TGA CTT TTG CCC CAT CTT C-3, (SEQ ID NO: 7) and 5 ') having a nucleotide sequence from 1 291 bp to 267 bp of the human adiponectin promoter region GCA AAA GTC AAA ACC A- 3, labeled with (SEQ ID NO: 8)), respectively [ ⁇ - 32 P] ATP (Amersham Biosciences) and T 4 polynucleotide kinase (Takara Shuzo), and the double-stranded Those were used as labeled probes.
- the underlined base sequence indicates P PRE ing.
- the binding reaction between the labeled probe and the protein synthesized in the in vitro system was performed in a 20 ⁇ l solution.
- the reaction solution 2 Omm HEP ES Ba Ffa ( ⁇ 8 ⁇ 0), 6 OmM KC 1, 1 mM Jichiosurei Torr consists composition of 1 0% glycerol, further 1 mu ⁇ poly (dl-dC), 1 mu 1
- the reaction mixture was prepared by adding a 200,000 cpm labeled probe to a synthesis reaction solution containing the nuclear receptor of Example 1 to make 20 ⁇ l. After mixing, the mixture was reacted at 25 ° C for 20 minutes, and further allowed to stand at 4 ° C for 15 minutes.
- the complex of the labeled probe and the nuclear receptor and the uncomplexed labeled probe were separated by electrophoresis using a 4% polyacrylamide gel.
- the electrophoresis was performed using 0.5XTBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA) at a voltage of 200 V for 90 minutes.
- the gel after the electrophoresis was dried and image-analyzed using a BAS2500 system (Fujisha Shin Kogyo).
- a competition reaction was also performed. Competition reactions were performed using unlabeled oligo DNA containing wild-type P PRE or oligo DNA with the same mutation introduced in P PRE as shown in Fig.
- the reaction was performed by adding a molar concentration to the reaction solution.
- the nucleotide sequence of the oligo DNA in which the mutation was introduced into PPRE was 5, -TGG TTT TGA CTT TTG tt C CAT CTT C-3 '(SEQ ID NO: 9) and 5, one GAA GAT GG aa CA AAA GTC AAA ACC A -3 '(array number 10). Mutated bases are shown in lower case.
- the underline attached to the nucleotide sequence indicates PRE.
- Fig. 8 shows the results. The arrow points to the slower band on the gel due to the binding of the labeled probe to the higher molecular weight protein.
- FIG. 9 shows the nucleotide sequence of LRH-RE in the promoter region of a gene that is reported to be regulated by LRH-1 (Mol. Cell 6, 507-515 (2000), Proc. Natl. Acad. Sci. USA 96, 6660-6665 (1999), J. Biol. Chem. 276, 24767-24773 (2001), J. Biol. Chem., 275, 17793-17799 (2000)).
- the sequence found in the human adiponectin promoter region differed only by one base from the LRH-RE present in the rat and human CYP7A1 gene promoter regions.
- FIG. 10 shows the location of the putative LRH-RE sequence.
- the putative LRH-RE sequence was located between 237 bp and 229 bp between the PRE and the transcription start site described above.
- the presence of the putative LRH-RE sequence in the human adiponectin promoter region suggests that the adiponectin promoter may be transcriptionally regulated by the nuclear receptor LRH-1. Therefore, in HEK293 cells, the above-mentioned p (-908) ZLUC was used as the reporter plasmid, and PPARy, RXRa, Then, an expression plasmid expressing LRH-1 was transiently expressed by the same method as that used in Example 2.
- LRH-1 had no effect alone, but enhanced the promotion of human adiponectin promoter 1 activity by the PPARyZ RXR dimer.
- FIG. 11 A reporter plasmid containing a mutation was prepared, and luciferase activity was measured (Fig. 11).
- a gel shift assay was performed to confirm that LRH-1 directly binds to the LEG-RE sequence, a regulator sequence found in the human adiponectin promoter region.
- Gel shift assay was performed by the same method as that used in Example 4.
- the LRH_1 protein used in the binding reaction was synthesized in an in vitro system using an expression plasmid expressing human LRH-1 as type III.
- Labeled probes include oligo DNA (5'—AAT AAG GGT CAA GGC CTG GAA AC AC—3 '(SEQ ID NO: 11) and 5' having a nucleotide sequence from 1 245 bp to 1 221 bp of the human adiponectin promoter region.
- oligo DNA (5'-AAT AAG GGT GGT) was used in which the same oligo DNA as that used for the labeled probe was used as a wild type, and a mutation was introduced into LRH-RE in the same manner as shown in Fig. 10.
- mice were cultured in a 6-well plate (Bettaton Dickinson) coated with type IV collagen, and 5 ⁇ g / m1 insulin, 0.5 mM isoptylmethylxanthine, Differentiation was induced in a medium containing 1 ⁇ dexamethasone. Cells 6 days after the start of differentiation induction were used for transformation experiments. Gene transfer was performed using LipofectAMINE 2000 (Invitrogen) according to the attached protocol.
- a ⁇ (—908) / LUC reporter with a wild-type human adiponectin promoter was used. Luciferase activity increased 19-fold. Treatment with 1 pioglitazone resulted in an additional 9-fold increase compared to no treatment.
- a reporter in which a mutation was introduced into the regulator sequence PPRE Fig. 6
- the luciferase activity was significantly reduced as compared with the wild type, and no effect of treatment with piodaritazone was observed.
- a reporter having a mutation in LRH-RE Fig.
- the regulatory sequence in the human adiponectin promoter region of the present invention is PPRE (Int. J. Obes. Relat. Metab. Disord. 24, 861-868 (2000)).
- PPRE Int. J. Obes. Relat. Metab. Disord. 24, 861-868 (2000).
- the 5 the base sequence located between the 273rd and 285th positions on the upstream side
- the LRH-RE (the same as the PPRE described above, the 5th base sequence located between the 229th and 237th positions on the upstream side)
- Nuclear receptors PPARo /, RXR, LRH- 1 Direct binding sequence and play a crucial role in the activation of the adiponectin promoter in adipocytes.
- Transformants transformed with a reporter plasmid in which an appropriate reporter gene is ligated to a DNA containing a promoter region including the regulator sequence are similar in expression to the physiological human adiponectin gene.
- Drugs for the treatment of human diseases Very useful for re-junging c
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03768257A EP1577388B1 (en) | 2002-12-26 | 2003-12-25 | Adiponectin promoter and use thereof |
AT03768257T ATE498684T1 (de) | 2002-12-26 | 2003-12-25 | Adiponectin-promoter und verwendung davon |
JP2004562943A JP4744882B2 (ja) | 2002-12-26 | 2003-12-25 | アディポネクチンプロモーターおよびその用途 |
AU2003292822A AU2003292822A1 (en) | 2002-12-26 | 2003-12-25 | Adiponectin promoter and use thereof |
US10/540,864 US7585623B2 (en) | 2002-12-26 | 2003-12-25 | Adiponectin promoter and use thereof |
DE60336076T DE60336076D1 (de) | 2002-12-26 | 2003-12-25 | Adiponectin-promoter und verwendung davon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-376589 | 2002-12-26 | ||
JP2002376589 | 2002-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004058970A1 true WO2004058970A1 (ja) | 2004-07-15 |
Family
ID=32677368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016772 WO2004058970A1 (ja) | 2002-12-26 | 2003-12-25 | アディポネクチンプロモーターおよびその用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7585623B2 (ja) |
EP (1) | EP1577388B1 (ja) |
JP (1) | JP4744882B2 (ja) |
AT (1) | ATE498684T1 (ja) |
AU (1) | AU2003292822A1 (ja) |
DE (1) | DE60336076D1 (ja) |
WO (1) | WO2004058970A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094866A1 (ja) * | 2004-03-31 | 2005-10-13 | Toudai Tlo, Ltd. | アディポネクチン発現誘導剤およびその利用 |
KR100610219B1 (ko) | 2004-07-30 | 2006-08-10 | 한국생명공학연구원 | 아디포넥틴 프로모터를 포함하는 벡터에 의해 형질전환된 세포를 이용한 세포신호 전달물질의 검색방법 |
JP2008154552A (ja) * | 2006-12-26 | 2008-07-10 | Mitsubishi Rayon Co Ltd | ロドコッカス属細菌用発現ベクター |
CN113671196A (zh) * | 2021-07-29 | 2021-11-19 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602007014389D1 (de) * | 2006-11-01 | 2011-06-16 | Medical Res And Infrastructure Fund Of The Tel Aviv | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase |
EP2020447A1 (en) | 2007-08-03 | 2009-02-04 | Zeltia, S.A. | Method for identifying compounds modulating adiponectin gene expression |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026363A1 (en) * | 1998-11-04 | 2000-05-11 | Genset | GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF |
WO2002083726A2 (en) * | 2001-04-10 | 2002-10-24 | Genfit | A novel zinc finger protein and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7445890B1 (en) * | 1998-12-24 | 2008-11-04 | Takeda Pharmaceutical Company Limited | Ucp-2 promoter and use thereof |
JP2000236886A (ja) * | 1998-12-24 | 2000-09-05 | Takeda Chem Ind Ltd | Ucp−2プロモーターおよびその用途 |
JP2001054386A (ja) * | 1999-08-17 | 2001-02-27 | Takeda Chem Ind Ltd | ヒトプロラクチン放出ペプチド受容体遺伝子プロモーターおよびその用途 |
-
2003
- 2003-12-25 DE DE60336076T patent/DE60336076D1/de not_active Expired - Lifetime
- 2003-12-25 JP JP2004562943A patent/JP4744882B2/ja not_active Expired - Lifetime
- 2003-12-25 AT AT03768257T patent/ATE498684T1/de not_active IP Right Cessation
- 2003-12-25 AU AU2003292822A patent/AU2003292822A1/en not_active Abandoned
- 2003-12-25 WO PCT/JP2003/016772 patent/WO2004058970A1/ja active Application Filing
- 2003-12-25 US US10/540,864 patent/US7585623B2/en not_active Expired - Lifetime
- 2003-12-25 EP EP03768257A patent/EP1577388B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026363A1 (en) * | 1998-11-04 | 2000-05-11 | Genset | GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF |
WO2002083726A2 (en) * | 2001-04-10 | 2002-10-24 | Genfit | A novel zinc finger protein and uses thereof |
Non-Patent Citations (1)
Title |
---|
DAS KALLOL ET AL: "Chromosomal Localization, Expression Pattern, and Promoter Analysis of the Mouse Gene Encoding Adipocyte-Specific Secretory Protein Acrp30", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, 2001, pages 1120 - 1129, XP002976274 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094866A1 (ja) * | 2004-03-31 | 2005-10-13 | Toudai Tlo, Ltd. | アディポネクチン発現誘導剤およびその利用 |
US7741080B2 (en) | 2004-03-31 | 2010-06-22 | Nissan Chemical Industries, Ltd. | Adiponectin expression-inducing agents and uses thereof |
KR100610219B1 (ko) | 2004-07-30 | 2006-08-10 | 한국생명공학연구원 | 아디포넥틴 프로모터를 포함하는 벡터에 의해 형질전환된 세포를 이용한 세포신호 전달물질의 검색방법 |
JP2008154552A (ja) * | 2006-12-26 | 2008-07-10 | Mitsubishi Rayon Co Ltd | ロドコッカス属細菌用発現ベクター |
CN113671196A (zh) * | 2021-07-29 | 2021-11-19 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
CN113671196B (zh) * | 2021-07-29 | 2023-09-12 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004058970A1 (ja) | 2006-04-27 |
EP1577388A4 (en) | 2006-02-01 |
EP1577388A1 (en) | 2005-09-21 |
DE60336076D1 (de) | 2011-03-31 |
EP1577388B1 (en) | 2011-02-16 |
US7585623B2 (en) | 2009-09-08 |
US20060084618A1 (en) | 2006-04-20 |
JP4744882B2 (ja) | 2011-08-10 |
ATE498684T1 (de) | 2011-03-15 |
AU2003292822A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6603149B2 (ja) | 心血管疾患を処置するためのニューレギュリン法および組成物 | |
Yang et al. | Effectiveness of the PPARγ agonist, GW570, in liver fibrosis | |
US6068976A (en) | Modulators of ob gene and screening methods therefor | |
US6300364B1 (en) | Medicinal compositions with cholesterol-lowering effect | |
Blad et al. | Biological and pharmacological roles of HCA receptors | |
WO1996029405A9 (en) | MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR | |
JP2004313198A (ja) | 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入 | |
Lundholm et al. | Gene expression profiling identifies liver X receptor alpha as an estrogen-regulated gene in mouse adipose tissue | |
KR20070112761A (ko) | 부신피질 자극 호르몬 유사체 및 관련 방법 | |
CN102741276A (zh) | 合成的肌肉抑制素肽拮抗剂 | |
JP2003516327A (ja) | アテローム性動脈硬化の予防および/または治療方法 | |
MXPA05001694A (es) | Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos. | |
KR20210131352A (ko) | 지방산 산화 장애(faod)의 치료에서의 ppar-델타 작용제의 용도 | |
WO2004058970A1 (ja) | アディポネクチンプロモーターおよびその用途 | |
JP2001519441A (ja) | 新規ビタミンd受容体関連ポリペプチド、かかるポリペプチドをコードする核酸配列及びその使用 | |
US20100015164A1 (en) | Compositions and Methods for Modulating Osteoblast Cell Differentiation and Bone Generation Through HIF-1a | |
JP4886506B2 (ja) | 転写因子klf5の活性化抑制作用を有する医薬 | |
US20180221443A1 (en) | Use of human small leucine zipper protein in osteogenesis procedure | |
US20010046966A1 (en) | Inhibition of adipogenesis | |
JP2000236886A (ja) | Ucp−2プロモーターおよびその用途 | |
AU5653299A (en) | Preventives and/or remedies for obesity | |
WO2001030368A1 (en) | Method for pr-39 peptide regulated stimulation of angiogenesis | |
Zuo et al. | TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction | |
WO2000039315A1 (fr) | Promoteur ucp-2 et son utilisation | |
CN110041271A (zh) | 雌激素调节剂及其制得的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004562943 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003768257 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006084618 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10540864 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003768257 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10540864 Country of ref document: US |